2-bromo-1-(2-fluoro-3-nitrophenyl)ethanone | 1336804-14-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-(2-fluoro-3-nitrophenyl)ethanone
• 英文别名: 2-Bromo-1-(2-fluoro-3-nitrophenyl)ethanone
• CAS: 1336804-14-8
• 化学式: C₈H₅BrFNO₃
• 分子量: 262.035
• InChiKey: LDBFARRGBDBBQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(2-fluoro-3-nitrophenyl)ethanone 在 三氯氧磷 作用下， 以 氯仿 、 丙酮 为溶剂， 生成 6-(2-Fluoro-3-nitrophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde
  参考文献：
  名称：

  Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors

  摘要：

  The activity of a series of imidazo[2,1-b]thiazole guanylhydrazones as inhibitors of p90 ribosomal S6 kinase 2 (RSK2) is described. It was found that a small subset of compounds show both potent inhibition of RSK2 kinase activity and tumor cell growth in vitro. Detailed study of one of the most active compounds indicates a high degree of selectivity for inhibition of RSK2 compared to a spectrum of other related kinases. Selective inhibition of the MCF-7 breast tumor cell line compared to MCF-10A non-transformed cells, as well as selective inhibition of the biomarker GSK3 provides evidence that the compounds can affect the RSK2 target in cells. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.07.001
• 作为产物：
  描述：

  2-溴-2'-氟苯乙酮 在 硝酸 作用下， 反应 1.0h， 生成 2-bromo-1-(2-fluoro-3-nitrophenyl)ethanone
  参考文献：
  名称：

  Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors

  摘要：

  The activity of a series of imidazo[2,1-b]thiazole guanylhydrazones as inhibitors of p90 ribosomal S6 kinase 2 (RSK2) is described. It was found that a small subset of compounds show both potent inhibition of RSK2 kinase activity and tumor cell growth in vitro. Detailed study of one of the most active compounds indicates a high degree of selectivity for inhibition of RSK2 compared to a spectrum of other related kinases. Selective inhibition of the MCF-7 breast tumor cell line compared to MCF-10A non-transformed cells, as well as selective inhibition of the biomarker GSK3 provides evidence that the compounds can affect the RSK2 target in cells. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.07.001

文献信息

• 用于激酶调节的化合物及其适应症
  申请人：普莱希科公司

  公开号：CN105228983A

  公开（公告）日：2016-01-06

  本发明提供了对蛋白激酶有活性的化合物以及调节蛋白激酶通路的方法，以及使用这些化合物治疗与蛋白激酶的异常活性相关的疾病或病症的方法。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：VIDAL Agnes

  公开号：US20160045505A1

  公开（公告）日：2016-02-18

  The present invention provides compounds of formula (I): (Formula (I)) or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.

  本发明提供了公式（I）的化合物：（公式（I）），或其药学上可接受的盐，互变异构体或立体异构体，其中变量如定义所述。本发明还提供了包括这种化合物的制药组合物和使用这种化合物治疗、预防、抑制、改善或根除由寄生虫引起的疾病的方法，例如利什曼病、非洲人类锥虫病和恰加斯病。
• Dimeric 2-aminoimidazoles are highly active adjuvants for gram-positive selective antibiotics against Acinetobacter baumannii
  作者：Santiana A. Marrujo、Veronica B. Hubble、Jingdong Yang、Man Wang、Ansley M. Nemeth、Samantha L. Barlock、Dane Juarez、Richard D. Smith、Roberta J. Melander、Robert K. Ernst、Mayland Chang、Christian Melander

  DOI：10.1016/j.ejmech.2023.115329

  日期：2023.3

  Previously, we reported aryl 2-aminoimidazole (2-AI) adjuvants that potentiate macrolide antibiotics against A. baumannii. Macrolide antibiotics are typically used to treat infections caused by gram-positive bacteria, but are ineffective against most gram-negative bacteria. We describe a new class of dimeric 2-AIs that are highly active macrolide adjuvants, with lead compounds lowering minimum inhibitory

  美国疾病控制与预防中心 (CDC) 报告称，自 2019 年以来，医院获得性感染增加了 65%。主要致病菌之一是革兰氏阴性菌鲍曼不动杆菌。此前，我们报道了芳基 2-氨基咪唑 (2-AI) 佐剂可增强大环内酯类抗生素对抗鲍曼不动杆菌的作用。大环内酯类抗生素通常用于治疗革兰氏阳性菌引起的感染，但对大多数革兰氏阴性菌无效。我们描述了一类新型二聚体 2-AI，它们是高活性大环内酯佐剂，其先导化合物可将针对鲍曼不动杆菌的最低抑制浓度 (MIC) 降低至或低于革兰氏阳性断点水平。母体二聚体将克拉霉素 (CLR) 对鲍曼不动杆菌5075 的 MIC 从 32 μg/mL 降低至 7.5 μM (3.4 μg/mL) 的 1 μg/mL，随后的结构活性关系 (SAR) 研究发现了几种化合物活动。该先导化合物在 1.5 μM (0.72 μg/mL) 时将 CLR MIC 降低至 2 μg/mL，远远超过母体二聚体和之前的先导芳基
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PARASITAIRES
  申请人：IRM LLC

  公开号：WO2014151784A1

  公开（公告）日：2014-09-25

  The present invention provides compounds of formula (I): (Formula (I)) or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.